Next Article in Journal
Dental Care in Times of the COVID-19 Pandemic: A Review
Previous Article in Journal
Public Knowledge, Attitudes, and Practice towards COVID-19 Pandemic in Saudi Arabia: A Web-Based Cross-Sectional Survey
Perspective

Research Supporting a Pilot Study of Metronomic Dapsone during Glioblastoma Chemoirradiation

IIAIGC Study Center, Burlington, VT 05408, USA
Received: 18 January 2021 / Revised: 8 February 2021 / Accepted: 10 February 2021 / Published: 16 February 2021
(This article belongs to the Section Cancer and Cancer-Related Research)
This short note presents previous research data supporting a pilot study of metronomic dapsone during the entire course of glioblastoma treatment. The reviewed data indicate that neutrophils are an integral part of human glioblastoma pathophysiology, contributing to or facilitating glioblastoma growth and treatment resistance. Neutrophils collect within glioblastoma by chemotaxis along several chemokine/cytokine gradients, prominently among which is interleukin-8. Old data from dermatology research has shown that the old and inexpensive generic drug dapsone inhibits neutrophils’ chemotaxis along interleukin-8 gradients. It is on that basis that dapsone is used to treat neutrophilic dermatoses, for example, dermatitis herpetiformis, bullous pemphigoid, erlotinib-related rash, and others. The hypothesis of this paper is that dapsone will reduce glioblastomas’ neutrophil accumulations by the same mechanisms by which it reduces dermal neutrophil accumulations in the neutrophilic dermatoses. Dapsone would thereby reduce neutrophils’ contributions to glioblastoma growth. Dapsone is not an ideal drug, however. It generates methemoglobinemia that occasionally is symptomatic. This generation is reduced by concomitant use of the antacid drug cimetidine. Given the uniform lethality of glioblastoma as of 2020, the risks of dapsone 100 mg twice daily and cimetidine 400 mg twice daily is low enough to warrant a judicious pilot study. View Full-Text
Keywords: dapsone; edema; glioblastoma; interleukin-8; myeloid derived suppressor cells; neutrophils dapsone; edema; glioblastoma; interleukin-8; myeloid derived suppressor cells; neutrophils
Show Figures

Figure 1

MDPI and ACS Style

Kast, R.E. Research Supporting a Pilot Study of Metronomic Dapsone during Glioblastoma Chemoirradiation. Med. Sci. 2021, 9, 12. https://0-doi-org.brum.beds.ac.uk/10.3390/medsci9010012

AMA Style

Kast RE. Research Supporting a Pilot Study of Metronomic Dapsone during Glioblastoma Chemoirradiation. Medical Sciences. 2021; 9(1):12. https://0-doi-org.brum.beds.ac.uk/10.3390/medsci9010012

Chicago/Turabian Style

Kast, Richard E. 2021. "Research Supporting a Pilot Study of Metronomic Dapsone during Glioblastoma Chemoirradiation" Medical Sciences 9, no. 1: 12. https://0-doi-org.brum.beds.ac.uk/10.3390/medsci9010012

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop